New Horizon Health (HKSE:06606) ROCE % : 1.22% (As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is New Horizon Health ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. New Horizon Health's annualized ROCE % for the quarter that ended in Jun. 2023 was 1.22%.

New Horizon Health ROCE % Historical Data

The historical data trend for New Horizon Health's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

New Horizon Health ROCE % Chart

New Horizon Health Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

ROCE %

-741.48

-43.88

-144.35

-219.76

-3.07

New Horizon Health Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
ROCE %	Get a 7-Day Free Trial				-375.68	-16.71	-5.65	-0.92	1.22

New Horizon Health ROCE % Calculation

New Horizon Health's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	-80.735	/	( ( (2882.235 - 236.761)	+	(2875.346 - 253.978) )	/ 2 )
	=	-80.735	/	( (2645.474	+	2621.368)	/ 2 )
	=	-80.735	/	2633.421
	=	-3.07 %

New Horizon Health's ROCE % of for the quarter that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2023 )		(Q: Dec. 2022 )		(Q: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2023 )		(Q: Dec. 2022 )		(Q: Jun. 2023 )
	=	38.614	/	( ( (2875.346 - 253.978)	+	(4020.199 - 290.381) )	/ 2 )
	=	38.614	/	( ( 2621.368	+	3729.818 )	/ 2 )
	=	38.614	/	3175.593
	=	1.22 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2023) EBIT data.

New Horizon Health (HKSE:06606) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

New Horizon Health ROCE % Related Terms

Thank you for viewing the detailed overview of New Horizon Health's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

New Horizon Health (HKSE:06606) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » New Horizon Health Ltd (HKSE:06606) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

6YZ:Germany

Address

400 Jiang’er Road, 13th Floor, T1 Building, Binjiang District, Zhejiang, Hangzhou, CHN, 310052

Website

https://ir.newhorizonbio.com

New Horizon Health Ltd is engaged in early cancer screening and in-home testing in China. The company has an early detection and cancer screening-focused pipeline of five products and product candidates with an emphasis on colorectal cancer screening. The company focuses on cancer prevention and cure through screening and early detection. It generates maximum revenue from ColoClear and Pupu Tube products.

Executives

Invesco Advisers, Inc.	2102 Investment manager
Chen Yiyou	2201 Interest of corporation controlled by you
Trident Trust Company (hk) Limited	2301 Trustee
Bancasa Holding Limited	2201 Interest of corporation controlled by you
Mst Development Limited	2101 Beneficial owner
Yao Naxin	2305 Beneficiary of a trust
Janus Henderson Group Plc	2102 Investment manager
Jpmorgan Chase & Co.	2106 Person having a security interest in shares
Invesco Developing Markets Fund	2106 Person having a security interest in shares
Zhu Yeqing	2101 Beneficial owner
Qiming Venture Partners V, L.p.
Qiming Gp V, L.p.
Qiming Corporate Gp V, Ltd.
Bei Jing Jun Qi Jia Rui Qi Ye Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you
Jun Lian Zi Ben Guan Li Gu Fen You Xian Gong Si	2201 Interest of corporation controlled by you

New Horizon Health (HKSE:06606) Headlines

No Headlines